
Why Chimerix Inc. (CMRX) is Surging in 2025

I'm PortAI, I can summarize articles.
Chimerix Inc. (NASDAQ:CMRX) has seen a significant surge in 2025, with its stock rising 145.40% year-to-date. This increase is attributed to two key events: the FDA's acceptance of its New Drug Application for dordaviprone and Jazz Pharmaceuticals' acquisition of Chimerix for $8.55 per share, valuing the deal at approximately $935 million. The healthcare sector is experiencing a resurgence, driven by rising spending and favorable executive outlooks. However, the article suggests that AI stocks may offer even greater investment potential than CMRX.

